Eos Energy Enterprises Inc vs Repligen Corporation Common Stock — how do they compare? Eos Energy Enterprises Inc trades at $1.93 (market cap $846.69M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 13.2× Eos Energy Enterprises Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 17 Days and Repligen Corporation Common Stock for 0 Days on average.
| EOSE | RGEN | |
|---|---|---|
Market Cap | $846.69M | $11.14B |
Volume | 19,531,326 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $19.19 | $194.57 |
52-Week Low | $1.95 | $102.87 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $1.18B | $11.02B |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.32, down 2.93% today, with bearish technical signals from moving averages despite oversold RSI readings. The company shows explosive revenue growth (from $114M in 2025 to $214M in 2026) but remains deeply unprofitable with negative gross margins and net losses. Recent catalysts include a $87M DOE loan advance and a Google partnership for a West Virginia energy project, driving positive media coverage.
The stock presents high-risk speculation with Wall Street analysts maintaining a cautious 'Hold' consensus (63.64%) despite a $7.10 price target implying 206% upside. Investment appeal hinges on EOSE scaling production and achieving profitability, but substantial execution risks and cash burn require careful monitoring. Current valuation at 4.46x sales appears stretched given persistent losses.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →